Unknown

Dataset Information

0

Waning of SARS-CoV-2 booster viral-load reduction effectiveness.


ABSTRACT: The BNT162b2 COVID-19 vaccine has been shown to reduce viral load of breakthrough infections (BTIs), an important factor affecting infectiousness. This viral-load protective effect has been waning with time post the second vaccine and later restored with a booster shot. It is currently unclear though for how long this regained effectiveness lasts. Analyzing Ct values of SARS-CoV-2 qRT-PCR tests of over 22,000 infections during a Delta-variant-dominant period in Israel, we find that this viral-load reduction effectiveness significantly declines within months post the booster dose. Adjusting for age, sex and calendric date, Ct values of RdRp gene initially increases by 2.7 [CI: 2.3-3.0] relative to unvaccinated in the first month post the booster dose, yet then decays to a difference of 1.3 [CI: 0.7-1.9] in the second month and becomes small and insignificant in the third to fourth months. The rate and magnitude of this post-booster decline in viral-load reduction effectiveness mirror those observed post the second vaccine. These results suggest rapid waning of the booster's effectiveness in reducing infectiousness, possibly affecting community-level spread of the virus.

SUBMITTER: Levine-Tiefenbrun M 

PROVIDER: S-EPMC8897467 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Waning of SARS-CoV-2 booster viral-load reduction effectiveness.

Levine-Tiefenbrun Matan M   Yelin Idan I   Alapi Hillel H   Herzel Esma E   Kuint Jacob J   Chodick Gabriel G   Gazit Sivan S   Patalon Tal T   Kishony Roy R  

Nature communications 20220304 1


The BNT162b2 COVID-19 vaccine has been shown to reduce viral load of breakthrough infections (BTIs), an important factor affecting infectiousness. This viral-load protective effect has been waning with time post the second vaccine and later restored with a booster shot. It is currently unclear though for how long this regained effectiveness lasts. Analyzing Ct values of SARS-CoV-2 qRT-PCR tests of over 22,000 infections during a Delta-variant-dominant period in Israel, we find that this viral-lo  ...[more]

Similar Datasets

| S-EPMC8940567 | biostudies-literature
| S-EPMC9383625 | biostudies-literature
| S-EPMC9597683 | biostudies-literature
| S-EPMC8809505 | biostudies-literature
| S-EPMC9716513 | biostudies-literature
| S-EPMC7332902 | biostudies-literature
| S-EPMC7836878 | biostudies-literature
| S-EPMC8178300 | biostudies-literature
| S-EPMC8755404 | biostudies-literature
| S-EPMC9384619 | biostudies-literature